Ware Olivia C — SEC Form 4 filings
SEC reporting owner CIK 1663771. 10 Form 4 filings on record with FilingPulse; latest filed 2026-06-26.
Transaction summary — filings shown
Covers all 10 filings on record, filed 2024-03-18 to 2026-06-26. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 5 legs across 2 filings — 18,402 shares, $1,155,842 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 17.
- Largest priced transaction: sale of 6,790 shares @ $55.36 ($375,907) in Arcellx, Inc., filed 2024-04-18.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Arcellx, Inc. (ACLX) | Director | 5 | — | 5 legs · 18,402 sh · $1,155,842 | 10 |
| Revance Therapeutics, Inc. (RVNC) | Director | 2 | — | — | 4 |
| Contineum Therapeutics, Inc. (CTNM) | Director | 3 | — | — | 3 |
Form 4 filings — Ware Olivia C
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-26 | 4 | Contineum Therapeutics, Inc. (CTNM) | Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2026-04-28 | 4 | Arcellx, Inc. (ACLX) | Disposition to issuer (D): 36,806 (derivative) · Disposition to issuer (D): 11,459 (derivative) · Disposition to issuer (D): 8,011 (derivative) · Disposition to issuer (D): 9,174 (derivative) | EDGAR |
| 2025-06-26 | 4 | Contineum Therapeutics, Inc. (CTNM) | Grant/award (A): 14,750 (derivative) @ $0 | EDGAR |
| 2025-05-30 | 4 | Arcellx, Inc. (ACLX) | Grant/award (A): 9,174 (derivative) @ $0 | EDGAR |
| 2025-02-06 | 4 | Revance Therapeutics, Inc. (RVNC) | Code (U): 16,675 @ $3.65 · Disposition to issuer (D): 15,000 | EDGAR |
| 2024-06-06 | 4 | Arcellx, Inc. (ACLX) | Grant/award (A): 8,011 (derivative) @ $0 | EDGAR |
| 2024-05-29 | 4 | Contineum Therapeutics, Inc. (CTNM) | Grant/award (A): 3,700 (derivative) @ $0 | EDGAR |
| 2024-05-03 | 4 | Revance Therapeutics, Inc. (RVNC) | Grant/award (A): 15,000 @ $0 · Grant/award (A): 23,458 (derivative) @ $0 | EDGAR |
| 2024-04-18 | 4 | Arcellx, Inc. (ACLX) | Option exercise (M): 9,402 @ $7.61 · Sale (S): 6,790 @ $55.36 · Sale (S): 2,612 @ $56.03 · Option exercise (M): 9,402 (derivative) @ $0 | EDGAR |
| 2024-03-18 | 4 | Arcellx, Inc. (ACLX) | Option exercise (M): 9,000 @ $7.61 · Sale (S): 1,900 @ $69.44 · Sale (S): 3,763 @ $70.36 · Sale (S): 3,337 @ $70.99 · Option exercise (M): 9,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1663771 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →